|Targets||p21-activated Kinases (PAKs)|
|Description||FRAX1036 is a highly selective PAK1 inhibitor that remarkably altered signaling to cytoskeletal-associated proteins. In vitro and in vivo tests with FRAX-1036 have shown that the small-molecule inhibitor can both deter proliferation in ovarian cancer cell|
|Appearance||White to off-white Solid|
|Synonyms||6-[2-chloro-4-(6-methylpyrazin-2-yl)phenyl]-8-ethyl-2-[2-(1-methylpiperidin-4-yl)ethylamino]pyrido[2,3-d]pyrimidin-7-one FRAX1036 SCHEMBL14928919 CS-5585 HY-19538|
|Solubility||Soluble in DMSO|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -47℃ for long term (months to years).|
|Shelf Life||2 years|
|Boiling Point||669.8±65.0 °C | Condition: Press: 760 Torr|
FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.
FRAX486, an effective PAK inhibitor, could improve epileptic seizures and sorts of other abnormal behaviors.
G-5555 is a selective PAK1 Inhibitor (Ki=3.7 nM) with low clearance (CLp = 3.4 mL/min/kg) and high oral bioavailability (F = 72%). IC50: PAK2= 11 nM, SIK2= 9 mM...
PAK4-IN-1, a substituted benzofuranyl compound, is an inhibitor of p21-activated kinases (PAKs). in MTT assay: IC50 ≤100 nM
FRAX1036 is a highly selective PAK1 inhibitor that remarkably altered signaling to cytoskeletal-associated proteins. In vitro and in vivo tests with FRAX-1036 h...
PF-3758309, also known as PF-03758309, is a PAK4 inhibitor, is also an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potent...
IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).
G-5555 hydrochloride is the hydrochloride salt of G-5555 which is a potent and selective p21-activated kinase 1 (PAK1) inhibitor (Ki= 3.7 nM). G-5555 was potent...
G‑5555, a pyridopyrimidine derivative, has been found to be a PAK1 inhibitor that could be significant in anticancer studies. Ki=3.7 nM.